Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
European Journal of Cancer · 2023-03 · 182 · 66-76
DOI: 10.1016/j.ejca.2022.12.028 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2023-03. Verfasst von Maud Velev und 26 weiteren Autor:innen. Beteiligte Einrichtung: Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Service d'oncologie médicale, Unive…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Antineoplastic Agents, Immunological, Bone Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Unicancer, Bristol-Myers Squibb.
Abstract (Originalsprache)
INTRODUCTION: Bone metastases (BM) in renal cell carcinoma (RCC) are associated with a poor prognosis based on retrospective studies evaluating antiangiogenic agents. Few data are available regarding immune checkpoint inhibitors (ICI) in patients with bone metastatic RCC. NIVOREN is a multicentre prospective study in which patients were treated with nivolumab after the failure of antiangiogenic agents. We aim to assess the impact of BM on prognosis, and the efficacy and safety of nivolumab in patients enrolled in the NIVOREN trial. MATERIALS AND METHODS: All patients with BM at inclusion were included in our study. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate (ORR), safety, and skeletal-related events (SRE). RESULTS: Among 720 patients treated with nivolumab, 194 presented BM at inclusion. The median follow-up was 23.9 months. Median OS was 17.9 months in patients with BM versus 26.1 months in patients without BM (p = 0.0023). The difference was not statistically significant after adjustment (p = 0.0707). The median PFS was shorter in patients with BM even after adjustment (2.8 versus 4.6 months, p = 0.0045), as well as the ORR (14.8% versus 23.3%). SRE occurred for 36% of patients with BM. A post-hoc analysis evaluating the impact of bone-targeting agents (BTA) on SRE incidence showed a significant benefit of BTA on the incidence of SRE (OR = 0.367, CI95% [0.151-0.895]). CONCLUSION: Nivolumab is associated with shorter PFS, and lower ORR in RCC patients with BM. Our study suggests that BTA in association with immunotherapy decreases the incidence of SRE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Service d'oncologie médicale, Université Paris Cité, 20 rue Leblanc, 75015, Paris, France. Electronic add…
- Centre Léon Bérard Direction de la Recherche Clinique et de l'Innovation, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France. Electronic address: Cecile.DALBAN@lyon.unicancer.fr.
- Institut Universitaire du Cancer Toulouse-Oncopole, Service d'oncologie médicale, 1 Av. Irène Joliot-Curie, 31100, Toulouse, France. Electronic address: chevreau.christine@iuct-oncopole.fr.
- Institut Paoli Calmettes, Service d'oncologie médicale, 232 Bd de Sainte-Marguerite, 13009, Marseille, France. Electronic address: gravisg@ipc.unicancer.fr.
- Centre Léon Bérard, université Lyon I, Service oncologie médicale, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France. Electronic address: sylvie.negrier@lyon.unicancer.fr.
- Centre Eugene Marquis, Service d'oncologie médicale, Av. de la Bataille Flandres-Dunkerque CS 44229, 35000, Rennes, France. Electronic address: b.laguerre@rennes.unicancer.fr.
Förderung
- Unicancer
- Bristol-Myers Squibb
Zitieren
APA
Velev, M., Dalban, C., Chevreau, C., Gravis, G., Negrier, S., Laguerre, B., Gross-Goupil, M., Ladoire, S., Borchiellini, D., Geoffrois, L., Joly, F., Priou, F., Barthelemy, P., Laramas, M., Narciso, B., Thiery-Vuillemin, A., Berdah, J. F., Ferrari, V., Dominique Thomas, Q., …, & Thibault, C. (2023). Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study. European Journal of Cancer, 182, 66-76. https://doi.org/10.1016/j.ejca.2022.12.028
Vancouver
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, et al. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study. European Journal of Cancer. 2023;182:66-76. doi:10.1016/j.ejca.2022.12.028
BibTeX
@article{Velev2023,
author = {Velev, Maud and Dalban, Cécile and Chevreau, Christine and Gravis, Gwenaelle and Negrier, Sylvie and Laguerre, Brigitte and Gross-Goupil, Marine and Ladoire, Sylvain and Borchiellini, Delphine and Geoffrois, Lionnel and Joly, Florence and Priou, Frank and Barthelemy, Philippe and Laramas, Mathieu and Narciso, Berangère and Thiery-Vuillemin, Antoine and Berdah, Jean-François and Ferrari, Victoria and Dominique Thomas, Quentin and Mione, Cécile and Curcio, Hubert and Oudard, Stephane and Tantot, Florence and Escudier, Bernard and Chabaud, Sylvie and Albiges, Laurence and Thibault, Constance},
title = {Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study},
journal = {European Journal of Cancer},
year = {2023},
volume = {182},
pages = {66--76},
doi = {10.1016/j.ejca.2022.12.028}
}
EUVIMED